A global, multicentre study by Droppa et al.77 compared 88 matched pairs of cangrelor-treated CS patients with patients managed with oral P2Y12 inhibition from the Intra-aortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial;79 30-day and 12-month mortality rates were 29.5% and 34.1% in cangrelor-treated patients and 36.4% and 47.1% in the control group (P = 0.34 and P = 0.08, respectively), and moderate and severe bleeding rates were 26% with cangrelor and 19.3% with oral P2Y12 inhibitors. The gene discussed is P2RY12; the disease is Cowden syndrome 1.